<DOC>
	<DOCNO>NCT01427881</DOCNO>
	<brief_summary>This phase II trial study well cyclophosphamide work prevent chronic graft-versus-host disease allogeneic peripheral blood stem cell transplant patient hematological malignancy . Giving chemotherapy total-body irradiation transplantation help stop growth cancer cell prevent patient 's immune system reject donor 's stem cell . Healthy stem cell donor infused patient help patient 's bone marrow make blood cell ; red blood cell , white blood cell , platelet . Sometimes , however , transplant donor cell cause immune response body 's normal cell , call graft-versus-host disease ( GVHD ) . Giving cyclophosphamide transplant may prevent happen may make chronic GVHD le severe .</brief_summary>
	<brief_title>Cyclophosphamide Prevention Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Patients With Hematological Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The primary objective study assess outcomes high-dose cyclophosphamide ( CY ) administer day 3 4 follow cyclosporine ( CSP ) human leukocyte antigen ( HLA ) -matched related unrelated mobilize blood cell transplantation total-body irradiation ( TBI ) busulfan ( BU ) -based conditioning . SECONDARY OBJECTIVES : I . The secondary objective study assess hematopoietic cell transplantation ( HCT ) outcomes withdrawal CSP accelerate patient without acute graft-versus-host disease ( GVHD ) . OUTLINE : Patients ' conditioning regimen determine Clinical Coordinator consultation attend physician . Based disease , patient receive either TBI fludarabine busulfan . PREPARATIVE REGIMEN : Patients receive TBI twice daily ( BID ) day -4 -3 -1 . Some patient also receive fludarabine intravenously ( IV ) daily day -5 -2 busulfan IV 3 hour daily ( QD ) 2 hour every 6 hour day -5 -2 . Patients may also undergo central nervous system ( CNS ) prophylaxis , testicular irradiation , and/or involved field irradiation per standard practice . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 per standard practice . GVHD PROPHYLAXIS : Patients receive cyclophosphamide IV 1-2 hour day 3-4 . Patients also receive cyclosporine IV every 12 hour every 8 hour begin day 5 taper day 56-126 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow day 180 annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Acute lymphocytic leukemia ( ALL ) morphologic first complete remission ( CR1 ) high risk feature define , limited : evidence adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , mixedlineage leukemia ( MLL ) rearrangement ; presence minimal residual disease ; progenitor Bcell immunophenotype ; high white blood cell ( WBC ) diagnosis ( &gt; 30,000/ul BALL ; &gt; 100,000/ul TALL ) ; delay attainment CR ( &gt; 4 week ) induction therapy ; additional clinical characteristic deem confer high relapse risk may discuss approve Principal Investigator ( PI ) Acute myeloid leukemia ( AML ) CR1 EXCEPT patient lowrisk feature define : Inv 16 ( 8 ; 21 ) absence ckit mutation Normal karyotype FLT3ITDnegative NPM1positive absence ckit mutation Patients respective `` lowrisk '' feature eligible , however , ( ) 1 cycle induction therapy require achieve CR1 ( ii ) patient precede myelodysplastic syndrome ( MDS ) myelofibrosis , ( iii ) secondary AML Acute leukemia 2nd great CR ( CR &gt; = 2 ) Refractory relapse AML = &lt; 10 % bone marrow blast circulate blast proven extramedullary disease AML transform myelodysplastic syndrome ( MDS ) &lt; 10 % bone marrow blast MDS follow high risk feature : High risk cytogenetics ( include , limited : 7q , inv [ 3 ] , [ 3q ] , del [ 3q ] complex karyotype ) International Prognostic Scoring System ( IPSS ) intermediate ( INT ) 2 great Treatmentrelated MDS Any phase MDS patient &lt; 21 year age Chronic myelogenous leukemia ( CML ) beyond 1st chronic phase resistant intolerant tyrosine kinase inhibitor ( adult ) phase ( pediatric &lt; 21 year ) Chronic myelomonocytic leukemia Philadelphianegative myeloproliferative disorder Lymphoma : relapse chemotherapysensitive ( complete partial response ) Hodgkin nonHodgkin lymphoma Multiple myelomastage III The patient legal representative must able understand give write informed consent DONORS : The donor must genotypically HLAidentical sibling , phenotypically HLAmatched firstdegree relative , unrelated donor molecularly match patient HLAA , B , C , DRB1 DONORS : Donors must meet selection criterion administration GCSF ( filgrastim ) apheresis define Foundation Accreditation Cell Therapy ( FACT ) screen per American Association Blood Banks ( AABB ) DONORS : Donors must capable give informed consent Prior autologous allogeneic stem cell transplant Performance status &gt; 2 ( Eastern Cooperative Oncology Group [ ECOG ] ) &lt; 50 ( Lansky ; patient &lt; 16 year old ) Uncontrolled infection ; protocol principal investigator ( PI ) final arbiter uncertainty regard whether previous infection adequate control allow enrollment study Positive serology human immunodeficiency virus ( HIV ) 1 , 2 human T cell lymphotropic virus ( HTLV ) 1 , 2 Left ventricular ejection fraction &lt; 45 % shorten fraction &lt; 25 % ; uncontrolled arrhythmia symptomatic cardiac disease Symptomatic pulmonary disease ; force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , diffusion capacity lung carbon monoxide ( DLCO ) = &lt; 50 % predict ( correct hemoglobin ) ; pulmonary function test perform , oxygen saturation &lt; 92 % room air Calculated ( CockcroftGault appropriate calculation pediatric patient ) serum creatinine clearance = &lt; 60 mL/min ; calculate CrCl 5060 mL/min , measure CrCl 24 hour urine collection &gt; 60 mL/min , measurement acceptable Total serum bilirubin twice upper normal limit Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 3fold high laboratory upper normal limit Female patient must negative serum pregnancy test ( woman child bearingpotential must test perform ) DONORS : Potential donor psychological , physiological , medical reason tolerate administration GCSF apheresis DONORS : Donors allergic filgrastim Escherichia ( E. ) coliderived protein DONORS : Donorrelated risk recipient DONORS : Positive antidonor lymphocytotoxic crossmatch DONORS : Donors positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>